Results 1 to 10 of about 51,024 (230)

Delayed Rifampin Administration in the Antibiotic Treatment of Periprosthetic Joint Infections Significantly Reduces the Emergence of Rifampin Resistance

Antibiotics, 2021
Rifampin is one of the most important biofilm-active antibiotics in the treatment of periprosthetic joint infection (PJI), and antibiotic regimens not involving rifampin were shown to have higher failure rates.
Ali Darwich, Franz-Joseph Dally, Mohamad Bdeir, Katharina Kehr, Thomas Miethke, Svetlana Hetjens, Sascha Gravius, Elio Assaf, Elisabeth Mohs   +8 more
doaj   +2 more sources

Structural basis of rifampin inactivation by rifampin phosphotransferase [PDF]

Proceedings of the National Academy of Sciences of the United States of America, 2016
Significance Rifampin phosphotransferases (RPH) belong to a recently identified antibiotic-resistance protein family that inactivates rifampin, the first-line drug against tuberculosis, by phosphorylation.
Hu Zhou, Youli Xiao, Chengyuan Wang
exaly   +3 more sources

Repeated pulmonary dosing of β-glucan-chitosan-PLGA nanoparticles controls Mycobacterium tuberculosis in mice [PDF]

Antimicrobial Agents and Chemotherapy
To address limitations in tuberculosis (TB) therapy, we developed an inhalable, immunomodulating, biocompatible nanoparticle system (β-C-P) encapsulating rifampin that targets alveolar macrophage.
Hilliard L. Kutscher, Maria Tamblin, Evon Smith, Arnav Shah, Patrick O. Kenney, Jessica L. Reynolds   +5 more
doaj   +2 more sources

Differential effects of cotreatment of the antibiotic rifampin with host-directed therapeutics in reducing intracellular Staphylococcus aureus infection [PDF]

PeerJ, 2020
Background Chronic infection by Staphylococcus aureus drives pathogenesis in important clinical settings, such as recurrent pulmonary infection in cystic fibrosis and relapsing infection in osteomyelitis. Treatment options for intracellular S.
Melissa D. Evans, Robert Sammelson, Susan McDowell   +2 more
doaj   +2 more sources

Comparing the Synergistic and Antagonistic Interactions of Ciprofloxacin and Levofloxacin Combined with Rifampin against Drug-Resistant Staphylococcus aureus: A Time–Kill Assay

Antibiotics, 2023
Background: Treatment of device-related infections by drug-resistant Staphylococcus aureus can be challenging, and combination therapy has been proposed as a potential solution.
Yu Ri Kang, Doo Ryeon Chung, Jae-Hoon Ko, Kyungmin Huh, Sun Young Cho, Cheol-In Kang, Kyong Ran Peck   +6 more
doaj   +1 more source

Comparative evaluation of critical concentrationsfor detecting borderline rifampin resistance in Mycobacterium tuberculosis

Annals of Clinical Microbiology, 2023
Background: Rifampin plays an important role in tuberculosis treatment. In recent years, the introduction of molecular testing techniques has enabled the rapid detection of rifampin resistance, leading to discrepancies with conventional methods.
Chang-Ki Kim, Hee Jae Huh, Jeong Su Park, Taesoung Kim, Jae Han Sohn   +4 more
doaj   +1 more source

Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine

Clinical and Translational Science, 2023
The fixed‐dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once‐daily treatment for all six major genotypes of chronic hepatitis C virus infection.
Matthew P. Kosloski, Hong Li, Stanley Wang, Federico Mensa, Jens Kort, Wei Liu   +5 more
doaj   +1 more source

Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France [PDF]

Journal of Bone and Joint Infection, 2020
Introduction: In patients undergoing a « debridement, antibiotics, and implant retention » (DAIR) procedure for acute staphylococcal prosthetic joint infection (PJI), post-operative treatment with rifampin has been associated with a higher probability of
A. Becker, A. Becker, L. Kreitmann, L. Kreitmann, C. Triffaut-Fillit, C. Triffaut-Fillit, F. Valour, F. Valour, F. Valour, F. Valour, E. Mabrut, E. Forestier, O. Lesens, C. Cazorla, S. Descamps, B. Boyer, C. Chidiac, C. Chidiac, C. Chidiac, S. Lustig, S. Lustig, S. Lustig, E. Montbarbon, C. Batailler, C. Batailler, C. Batailler, T. Ferry, T. Ferry, T. Ferry, T. Ferry   +29 more
doaj   +1 more source

In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection

Microbiology Spectrum, 2021
After staphylococci, streptococci and enterococci are the most frequent causes of periprosthetic joint infection (PJI). MICs and minimum biofilm bactericidal concentrations of rifampin, rifabutin, and rifapentine were determined for 67 enterococcal and ...
Mariana Albano, Melissa J. Karau, Kerryl E. Greenwood-Quaintance, Douglas R. Osmon, Caitlin P. Oravec, Daniel J. Berry, Matthew P. Abdel, Robin Patel   +7 more
doaj   +1 more source

Rifampin-Associated Renal Failure

Annals of Internal Medicine: Clinical Cases, 2023
Rifampin is an effective and widely used for the treatment of both active and latent tuberculosis. Although significant side effects are rare, severe side effects such as acute renal failure have been reported in the literature, usually secondary to ...
Kathleen Miller, Helmut Rennke, Eugene Richardson   +2 more
doaj   +1 more source